Information checked: 5 November 2026.
Retatrutide is a molecule being investigated by Eli Lilly in clinical research. Its scientific evidence, development status and study information should be considered separately from products advertised under names such as VLS Retatrutide. A commercial product name does not establish that the product is an authorised medicine or the same material used in a clinical trial.
What the research shows
Retatrutide acts at GIP, GLP-1 and glucagon receptors. In a randomised, placebo-controlled phase 2 study published in the New England Journal of Medicine, researchers investigated its effects and safety in adults with obesity.
The study reported body-weight outcomes and adverse events within a defined research setting. Its findings concern the intervention and participants studied. They do not verify the identity, purity, sterility or clinical suitability of an independently marketed VLS product.
Current development status
Lilly’s public information about retatrutide describes it as investigational and states that it has not been approved as a medicine. Development and regulatory information can change, so dated claims should be checked against the original source.
An online listing or a “research use only” label does not demonstrate approval for human use. Published clinical results should not be presented as an endorsement of a seller or a particular commercial product.
Understanding clinical-trial information
Lilly’s official clinical-trial portal provides information about its research studies. Individual records describe their purpose, locations, enrolment status and eligibility requirements.
A listed study may have completed recruitment. Participation depends on the study’s criteria and assessment by its research team; finding a record does not guarantee eligibility or access.
Checking medicine information in the UK
The MHRA’s medicine-information guidance explains how to find product information, patient leaflets and scientific assessment reports.
When evaluating any claim, identify the exact product or study concerned and what the cited source actually establishes. Evidence about a molecule, a trial intervention and a commercially labelled product should remain clearly distinguished.